Sanofi (SNYNF)
OTCMKTS
· Delayed Price · Currency is USD
106.45
0.00 (0.00%)
Apr 23, 2025, 4:00 PM EDT
Sanofi Revenue
Sanofi had revenue of 10.61B EUR in the quarter ending March 31, 2025, a decrease of -4.61%. This brings the company's revenue in the last twelve months to 45.17B, down -2.42% year-over-year. In the year 2024, Sanofi had annual revenue of 44.29B with 7.73% growth.
Revenue (ttm)
45.17B EUR
Revenue Growth
-2.42%
P/S Ratio
2.66
Revenue / Employee
544.97K EUR
Employees
82,878
Market Cap
129.74B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 44.29B | 3.18B | 7.73% |
| Dec 31, 2023 | 41.11B | 805.00M | 2.00% |
| Dec 31, 2022 | 40.30B | 1.13B | 2.88% |
| Dec 31, 2021 | 39.18B | 1.81B | 4.83% |
| Dec 31, 2020 | 37.37B | -262.00M | -0.70% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| SS Innovations International | 20.65M |
| Endo Inc. | 1.76B |
| Veradigm | 588.02M |
| Elite Pharmaceuticals | 70.00M |
| Northwest Biotherapeutics | 1.38M |
| Glass House Brands | 200.90M |
| BioStem Technologies | 301.83M |
| American Oncology Network | 1.76B |
Sanofi News
- 8 hours ago - Sanofi Sales, Profit Beat Expectations on Higher Demand for Skin, Asthma Drug - WSJ
- 11 hours ago - Sanofi beats top-line and bottom-line estimates; reaffirms FY25 outlook - Seeking Alpha
- 11 hours ago - Sanofi's quarterly profit beats estimates on Dupixent boost, newer products - Reuters
- 11 hours ago - Press Release: Sanofi: strong Q1 performance and 2025 guidance confirmed - GlobeNewsWire
- 1 day ago - Novartis and Sanofi CEOs say EU should raise drug prices in face of tariffs - Reuters
- 1 day ago - Pharma bosses call for higher drug prices in EU to counter tariff threat - Financial Times
- 6 days ago - Sanofi-Regeneron's Dupixent gets FDA's nod for skin condition - Reuters
- 6 days ago - Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria - GlobeNewsWire